Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2016-12-14 Regulatory Filings
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from Innoviva, Inc. addressed to the SEC staff, specifically responding to comments on the company's previously filed Form 10-K for the fiscal year ended December 31, 2015. The letter discusses accounting policies and provides supplemental information requested by the SEC staff. It references the 10-K filing but does not contain the full annual report or financial statements itself. The document is a correspondence related to regulatory review and compliance rather than the report itself. It is not a certification letter but a detailed response to SEC comments. Given the nature of the document as a regulatory correspondence responding to SEC comments on a 10-K, it fits best under Regulatory Filings (RNS), which is the fallback category for such communications that do not constitute the actual report or a different specific filing type.
2016-12-14 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-12-09 English
Regulatory Filings 2016
Regulatory Filings
2016-12-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions an "Other Events" section describing a press release about a regulatory submission by GlaxoSmithKline and Innoviva. There are no financial statements or detailed financial data included, and the document is relatively short (2659 characters). It primarily serves as an announcement of an event rather than a detailed financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-12-02 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes an announcement of the Japanese Ministry of Health, Labor and Welfare's approval of a medication, which is an event update rather than a financial report or detailed filing. The document is short (2866 characters) and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. This fits the profile of a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-12-02 English
FORM 4 -
Director's Dealing
2016-11-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.